Table 2.

Comparison of clinical characteristics of patients with SLE risk probability score > 7 and ≤ 7

Variable mean ± SD, n (%), median (IQR)	SLE risk probability > 7 (n = 1,031)	SLE risk probability ≤ 7 (n = 130)	P value
Age, years	33.1 ± 10.2	34.8 ± 9.4	0.069
Female	920 (89.2)	119 (90.8)	0.574
Diagnosis duration, years	4 (2,7)	5.5 (3,9)	0.576
Age of diagnosis	26.5 (8.4)	28.1 (9.0)	0.129
Diabetes	9 (25.7)	148 (35.7)	0.236
Hypertension	3 (12.5)	35 (9.7)	0.656
SLERPI variables
Malar rash or maculopapular rash	664 (64.4)	12 (9.16)	< 0.001
SCLE or DLE	240 (23.3)	11 (8.4)	< 0.001
Alopecia	563 (54.6)	21 (16.0)	< 0.001
Mucosal ulcers	715 (61.5)	0 (0.0)	NA
Arthritis	696 (67.5)	61 (46.5)	< 0.001
Serositis	209 (20.3)	10 (7.6)	< 0.001
Leucopenia	219 (21.2)	19 (14.5)	0.072
Thrombocytopenia or AIHA	154 (14.9)	0 (0.0)	NA
Neurological disorder	120 (11.6)	7 (5.3)	0.030
Proteinuria	427 (41.4)	0 (0.0)	NA
ANA	912 (88.5)	111 (84.7)	0.216
Low C3 and C4	232 (22.5)	7 (5.3)	< 0.001
Immunological disorder	480 (46.5)	21 (16.0)	< 0.001
Interstitial lung disease	58 (5.6)	8 (6.1)	0.823
SLERPI score	13.1 ± 3.8	5.6 ± 1.2	< 0.001
SLEDAI score	11 (4—20)	4 (1—8)	< 0.001
SLICC -DI	2 (1- 3)	1 (0—1)	0.228
Medications
Systemic steroids	520 (88.6)	56 (81.2)	0.075
Hydroxychloroquine	509 (86.7)	63 (91.3)	0.280
Cyclophosphamide	215 (36.6)	25 (36.2)	0.949
Azathioprine	297 (50.6)	35 (50.7)	0.984
Mycophenolate mofetil	64 (13.1)	4 (5.8)	0.083
Methotrexate	51 (10.9)	17 (25.0)	0.001

AIHA autoimmune hemolytic anemia, ANA anti-nuclear antibodies, C3 complement 3, C4 complement 4, SLEDAI Systemic Lupus Erythematosus Disease Activity Index, SLERPI Systemic Lupus Erythematosus Risk Probability Index. SLICC-DI Systemic Lupus Erythematosus International Collaborating Clinics damage index, DLE discoid lupus erythematosus, SCLE Subacute cutaneous lupus erythematosus